Dr. Mark Gonzalgo is Assistant Professor of Urology and Oncology at The Brady Urological Institute. He joined the faculty after completing his general surgery and urology training at Johns Hopkins and a fellowship in Urologic Oncology at Memorial Sloan-Kettering Cancer Center.

Dr. Gonzalgo is a board-certified and fellowship-trained urologic oncologist who treats patients with prostate, bladder, kidney, and testis cancers. He has expertise in robotic prostatectomy, robotic cystectomy for bladder cancer, nerve-sparing radical retropubic prostatectomy, orthotopic urinary diversion, and laparoscopic kidney surgery.

As a member of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Dr. Gonzalgo works closely with medical oncologists, radiation oncologists, and research scientists to offer cancer patients the most advanced treatment available. This mutli-disciplinary approach to cancer treatment provides patients with highly individualized surgical and medical options ranging from open, laparoscopic, or robotic surgery to chemotherapy or radiation therapy.

Dr. Gonzalgo is a recognized expert in the field of DNA methylation and is particularly interested in developing new therapeutic approaches for cancer treatment. He has carried out pioneering research on the molecular biology and early detection of prostate, bladder, and kidney cancer and has published extensively on the scientific and clinical aspects of these diseases.